Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Non-randomized Prospective Phase II Study of Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency

Next Previous
Search
Trial Profile

A Non-randomized Prospective Phase II Study of Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olaparib (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca

Most Recent Events

  • 12 Feb 2025 Status changed from recruiting to withdrawn prior to enrolment. ( Sponsor terminated due to Olaparib losing patent)
  • 17 Jan 2024 Planned End Date changed from 1 Nov 2029 to 31 Dec 2029.
  • 17 Jan 2024 Planned primary completion date changed from 1 Nov 2027 to 31 Dec 2027.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top